Acute Myeloid Leukemia
Researchers determined 3 levels of somatic mutation clearance based on VAF of residual mutations at CR.
Findings from previous studies suggests that multiparameter flow cytometric minimal residual disease may be used to predict outcomes in acute myeloid leukemia.
The most frequently observed adverse events among patients treated with sorafenib were cytopenias and skin rashes.
Previous studies showed that romiplostim for thrombocytopenia in MDS improved hematologic outcomes but may increase the risk of AML.
The risk of AML decreased after 2 years, returning to baseline within 6 years of WDTC diagnosis, but the risk of CML remained elevated for up to 10 years.
Researchers randomly assigned 597 patients with newly diagnosed AML to receive intermediate- or conventional-dose cytarabine plus homoharringtonine and daunorubicin.
At the end of maintenance, 57% and 64% of patients remained in the midostaurin arm or the placebo arm, respectively. There were 16 relapse events after maintenance in the midostaurin arm and 7 relapses and 2 deaths in the placebo arm.
Elias Jabbour, MD, discusses the latest developments in the treatment of acute and chronic leukemia from the ASH 2017 meeting.
For a meta-analysis, researchers evaluated outcomes data from 9 studies consisting of 6762 patients with an acute leukemia to determine whether HSCT is superior to UCBT.
Gilteritinib inhibits the FLT3 mutations observed in up to one-third of patients with AML, FLT3 internal tandem duplication, and the FLT3 tyrosine kinase domain.
Standard cytotoxic chemotherapy remains the standard treatment for AML, though a large proportion of patients relapse and/or develop resistance to conventional therapy, indicating a need for new treatments.
Researchers analyzed human AML samples to determine potential selective targets in leukemia stem cells, the source of resistance to standard chemotherapy.
Guadecitabine, a next-generation hypomethylating agent, has been shown to have a longer half-life and to prolong periods of exposure more than its predecessors.
Among patients with R/R disease, 19.3% achieved complete remission (CR) and had a median overall survival of 19.7 months.
Approval was based on data from a randomized phase 3 trial in which researchers compared the efficacy of the daunorubicin-cytarabine combination with that of a standard regimen.
The US Food and Drug Administration approved enasidenib for the treatment of adult patients with relapsed or refractory AML with an IDH2 mutation.
The US Food and Drug Administration granted orphan drug designation to gilteritinib for the treatment of AML.
Adding midostaurin — a multi-targeted kinase inhibitor — to chemotherapy prolongs overall survival (OS) among patients with newly diagnosed AML and an FLT3 mutation.
The data showed a higher rate of death, including fatal infections, in the vadastuximab talirine arm compared with the chemotherapy-only arm.
The FDA approved midostaurin for patients with newly diagnosed, FLT3 mutation-positive acute myeloid leukemia.
Study results support development of therapeutics that are targeted and based on individual genetic variants and would generalize across patient-groups in AML.
The FDA has granted Priority Review to the NDA for midostaurin (PKC412) for the treatment of adults with acute myeloid leukemia (AML).
This collaborative trial will test several new drugs in the clinical setting at major research institutions.
Maintenance therapy with norethandrolone improves survival of elderly patients with acute myeloid leukemia (AML) without increasing toxicity.
Dr Isabel Cunningham reviews and highlights important, recently published articles with recommendations for treating elderly patients with acute myeloid leukemia (AML).
In patients with acute myelogenous leukemia, the highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor venetoclax is active.
The FDA granted Breakthrough Therapy Designation to pracinostat in combination with azacitidine for the treatment of acute myeloid leukemia (AML).
Vyxeos (CPX-351) statistically significantly improved overall survival as compared with the cytarabine and daunorubicin 7+3 regimen.
The FDA has granted Breakthrough Therapy Designation to midostaurin (PKC412) for acute myeloid leukemia (AML).
First-line monotherapy with low-dose gemtuzumab ozogamicin appeared to be superior in older patients with acute myeloid leukemia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Resveratrol and Cancer
- Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
- Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
- ARID1A Mutations Might Predict Tumor Response to Immunotherapy
- Global Burden of Myeloma Increasing, Access to Treatments Lacking
- ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks
- Adding Rituximab to Prednisolone May Improve Long-Term Response in Immune Thrombocytopenia
- FDA Updates Restrictions for Pembrolizumab, Atezolizumab in Urothelial Carcinoma
- Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer
- Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer